middle.news
How Will Arovella’s $15M Raise Accelerate Its First-in-Human iNKT Cell Trial?
9:51pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
How Will Arovella’s $15M Raise Accelerate Its First-in-Human iNKT Cell Trial?
9:51pm on Friday 29th of August, 2025 AEST
Key Points
Net loss narrowed 14.1% to $7.5 million in FY25
Revenue increased to $136,000 from $17,000 prior year
Completed $15 million share placement to fund clinical development
Lead program ALA-101 advancing to first-in-human phase 1 trial with positive FDA pre-IND feedback
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE